Aktywność biologiczna modyfikownych nukleozydów. Część 2

• Autorzy: Szlenkier M.

Warianty tytułu

EN

Biological activity of modified nucleosides. Part 2

• Języki publikacji: PL

Abstrakty

EN

Part II of the review describes biological activities of nucleosides modified in the position 2’ and/or 3’ of a sugar moiety including 2’- and/or 3’-deoxy, 2’,3’-dideoxydidehydro and 2’-β-C-methylated derivatives. Analogues with a changed configuration in the sugar residue and others sugar modifications will be a subject of the part III of the review. Together with the part I it would be a short but possibly comprehensive review of nucleosides’ biological activities. In the group of analogues modified in the position 2’ and/or 3’ of the sugar moiety the following derivatives among others are listed: AZT (zidovudine) – one of the key nucleoside reverse transcriptase inhibitors (NRTI), which are the core of highly active antiretroviral therapy (HAART) against virus HIV; didanosine (ddI) – another potent NRTI with medical importance; stavudine – FDA approved NRTI; zalcitabine – historically important NRTI, however, because of a high mitochondrial toxicity is no longer in use; puromycin – a wide spectrum antibiotic which causes premature chain termination during translation, isolated from Streptomyces alboniger; gemcitabine – chemotherapy medication developed by Eli Lilly and Company and used to treat ovarian, breast, pancreas, bladder cancer and non-small cell lung carcinoma; cordycepin – the most intriguing analogue extracted from Cordyceps sp. known to traditional Chinese medicine (TCM) for centuries, possessing multi-activity against different cancer types; cladribine – used in the treatment of chronic lymphocytic leukemia, cutaneous T-cell lymphoma, hairy cell leukemia and non-Hodgkin’s lymphomas; valopicitabine – a prodrug form of 2’-C-methylcytidine, which was a promising HCV treatment agent, however, it was held during clinical trials and finally sofosbuvir developed by M.J. Sofia from Pharmasset Inc.– a ProTide prodrug form of 2’-deoxy-2’-fluoro-β-C-methyluridine 5’-monosphate, which revolutionized HCV infection therapy.

Słowa kluczowe

PL

nukleozydy modyfikowane; aktywność biologiczna; cele molekularne; mechanizm działania

EN

modified nucleosides; biological activity; molecular targets; mechanism of action

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2018
• Tom: [Z] 72, 5-6
• Strony: 245--264
• Opis fizyczny: Bibliogr. 72 poz., schem.

Twórcy

autor

Szlenkier M.

• Instytut Chemii Bioorganicznej Polskiej Akademii Nauk w Poznaniu, ul. Z. Noskowskiego 12/14, 61-704 Poznań

Bibliografia

• [1] R.P. Agarwal, A.M. Mian, Biochem. Pharmacol., 1991, 42, 905.
• [2] L.A. Agrofoglio, S.R. Challand, Acyclic, Carbocyclic and L-nucleosides, Kluwer Academic Publishers, Dordrecht 1998.
• [3] R.J. Pomerantz, Clin. Infect. Dis., 2002, 34, 91.
• [4] K. Connolly, S. Hammer, Antimicrob. Agents Chemother., 1992, 36, 245.
• [5] E.M. Scholar, W.B. Pratt, The Antimicrobial Drugs, Second Edition, Oxford University Press, New York 2000.
• [6] S.G. Sarafianos, B. Marchand, K. Das, D.M. Himmel, M.A. Parniak, S.H. Hughes, E. Arnold, J. Mol. Biol., 2009, 385, 693.
• [7] S.G. Sarafianos, A.C. Jr. Clark, K. Das, S. Tuske, J.J. Birktoft, E. Arnold, EMBO J., 2002, 21, 6614.
• [8] V.R. Sirivolu, S.K. Vernekar, T. Ilina, N.S. Myshakina, M.A. Parniak, Z. Wang, J. Med. Chem., 2013, 56, 8765.
• [9] H. Mitsuya, S. Broder, Proc. Natl. Acad. Sci. USA, 1986, 83, 1911.
• [10] R. Yarchoan, H. Mitsuya, R.V. Thomas, J.M. Pluda, N.R. Hartman, C.F. Perno, K.S. Marczyk, J.P. Allain, D.G. Johns, S. Border, Science, 1989, 245, 412.
• [11] G. Beskid, B. Eskin, R. Cleeland, J. Siebelist, A. Cappetta, A.D. Hill, R.H. Geiger, Antimicrob. Agents Chemother., 1981, 19, 424.
• [12] J.P. Horowitz, J. Chua, M. Noel, J.T. Donatt, J. Org. Chem., 1967, 32, 817.
• [13] C.-F. Perno, R. Yarchoan, D.A. Cooney, N.R. Hartman, S. Gartnar, M. Popovic, Z. Hao, T.L. Gerrard, Y.A. Wilson, D.G. Johns, S. Broder, J. Exp. Med., 1988, 168, 1111.
• [14] C.-H. Chen, Y.-C. Chen, J. Biol. Chem., 1989, 264, 11934.
• [15] J.E. Dahlberg, H. Mitsuya, S.B. Blam, S. Broder, S.A. Aaronson, Proc. Nati. Acad. Sci. USA, 1987, 84, 2469.
• [16] J.T. Patton, N.L. Davis, G.W. Wertz, J. Gen. Virol., 1983, 64, 743.
• [17] M.A. Waqar, M.J. Evans, K.F. Manly, R.G. Hughes, J.A. Huberman, J. Cell Physiol., 1984, 121, 402.
• [18] E.L. White, W.B. Parker, L.J. Macy, S.C. Shaddix, G. McCaleb, et al., Biochem. Biophys. Res. Commun., 1989, 161, 2, 393.
• [19] K.B. Frank, P.A. McKernan, R.A. Smith, D.F. Smee, Antimicrob. Agents Chemother., 1987, 31, 1369.
• [20] S. Suzuki, B. Lee, W. Luo, D. Tovell, M.J. Robins, D.L. Tyrrell, Biochem. Biophys. Res. Commun., 1988, 156, 1144.
• [21] J.C. Wu, M. Chernov, R.E. Boehme, R.T. Suttmann, M.J. McRoberts, Antimicrob. Agents Chemother., 1988, 32, 1887.
• [22] M. Baba, R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, Biochem. Biophys. Res. Commun., 1987, 145, 1080.
• [23] J.P. Horwitz, J. Chua, M.A. Da Rooge, M. Noel, Tetrahedron Lett., 1964, 5, 2725.
• [24] M.M. Mansuri, M.J. Hitchcock, R.A. Buroker, C.L. Bregman, I. Ghazzouli, J.V. Desiderio, J.E. Starret, R.Z. Sterzycki, J.C. Martin, Antimicrob. Agents Chemother., 1990, 34, 637.
• [25] M.J. Browne, K.H. Mayer, S.B. Chafee, M.N. Dudley, M.R. Posner, S.M. Steinberg, K.K. Graham, S.M. Geletko, S.H. Zinner, S.L. Denman, L.M. Dunkle, S. Kaul, C. McLaren, G. Skowron, N.M. Kouttab, T.A. Kennedy, A.B. Weitberg, G.A. Curt, J. Infect. Dis., 1993, 167, 21.
• [26] M. Baba, R. Pauwels, P. Herdewijn, E. De Clercq, J. Desmyter, M. Vandeputte, Biochem. Biophys. Res. Commun., 1987, 142, 128.
• [27] J. Balzarini, G.J. Kang, M. Dalal, P. Herdewijn, E. De Clercq, S. Broder, D.G. Johns, Mol. Pharmacol., 1987, 32, 162.
• [28] N. Dyatkina, S. Minassian, M. Kukhanova, A. Krayevsky, M. von Janta-Lipinsky, Z. Chidgeavadze, R. Beabealashvilli, FEBS Lett., 1987, 219, 151.
• [29] W.-D. Menga, F.-L. Qing, Curr. Top. Med. Chem., 2006, 6, 1499.
• [30] A. Van Aerschot, P. Herdewijn, J. Balzarini, R. Pauwels, E. De Clercq, J. Med. Chem., 1989, 32, 743.
• [31] R.J. Suhadolnik, Nucleoside Antibiotics, Wiley, New York 1970.
• [32] K.-I. Takatsuki, S. Ohgushi, S. Kohmoto, K. Kishikawa, M. Yamamoto, Nucleos. Nucleot. Nucl., 2006, 25, 719.
• [33] L.W. Hertel, J.S. Kroin, J.W. Misner, J.M. Tustin, J. Org. Chem., 1988, 53, 2406.
• [34] P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, W. Plunkett, Cancer Res. 1991, 15, 6110.
• [35] S. Noble, K.L. Goa, Drugs 1997, 54, 447.
• [36] N.M. Cerqueira, P.A. Fernandes, M.J. Ramos, Chem. Eur. J., 2007, 13, 8507.
• [37] E. Mini, S. Nobili, B. Caciagli, I. Landini, T. Mazzei, Ann. Oncol., 2006, 17, Supl. 5, 7.
• [38] S. Dyawanapelly, A. Kumar, M.K. Chourasia, Crit. Rev. Ther. Drug Carrier Syst., 2017, 34, 63.
• [39] R.D. Dubey, A. Saneja, P.K. Gupta, P.N. Gupta, Eur. J. Pharm. Sci., 2016, 93, 147.
• [40] I. Lefebvre, C. Perigaud, A. Pompon, A.-M. Aubertin, J.-L. Girardet, A. Kirn, G. Gosselin, J.-L. Imbach, J. Med. Chem., 1995, 38, 3941.
• [41] T.P. Prakash, M. Prhavc, A.B. Eldrup, P.D. Cook, S.S. Carroll, D.B. Olsen, M.W. Stahlhut, J.E. Tomassini, M. MasCoss, S.M. Galloway, C. Hilliard, B. Bhat, J. Med. Chem., 2005, 48, 1199.
• [42] K.G. Cunningham, W. Manson, F.S. Spring, S.A. Hutchinson, Nature, 1950, 166, 949.
• [43] H.S. Tuli, S.S. Sandhu, A.K. Sharma, 3 Biotech., 2014, 4, 1.
• [44] H.-C. Lo, C. Hsieh, F.-Y. Lin, T.-H. Hsu, J. Tradit. Complement. Med., 2013, 3, 16.
• [45] H.S. Tuli, A.K. Sharma, S.S. Sandhu, D. Kashyap, Life Sci., 2013, 93, 863.
• [46] E.N. Kodama, R.P. McCaffrey, K. Yusa, H. Mitsuya, Biochem. Pharmacol., 2000, 59, 273.
• [47] Y. Liao, J. Ling, G. Zhang, F. Liu, S. Tao, Z. Han, S. Chen, Z. Chen, H. Le, Cell Cycle, 2015, 14, 761.
• [48] S. Shin, S. Lee, J. Kwon, S. Moon, S. Lee, C.K. Lee, K. Cho, N.J. Ha, K. Kim, Immune. Netw., 2009, 9, 98.
• [49] J.W. Jeong, C.Y. Jin, C. Park, S.H. Hong, G.Y. Kim, Toxicol. In Vitro, 2011, 25, 817.
• [50] S.K. Vodnala, T. Lundback, E. Yeheskieli, B. Sjoberg, A.L. Gustavsson, R. Svensson, G.C. Olivera, A.A. Eze, H.P. de Konig, L.G.J. Hammarstrom, M.E. Rottenberg, J. Med. Chem., 2013, 56, 9861.
• [51] S.M. Liang, Y.J. Lu, B.S. Ko, Y.J. Jan, S.K. Shyue, S.F. Yet, J.Y. Liou, Sci. Rep., 2017, 7, 43930.
• [52] C. Sauter, N. Lamanna, M.A. Weiss, Expert Opin. Drug Metab. Toxicol., 2008, 4, 1217.
• [53] C. Tortorella, M. Rovaris, M. Filippi, Curr. Opin. Investig. Drugs., 2001, 2, 1751.
• [54] H. Venner, Chem. Ber., 1960, 93, 140.
• [55] M. Ikehara, H. Tada, J. Am. Chem. Soc., 1965, 87, 606.
• [56] L.F. Christensen, A.D. Broom, M.J. Robins, A. Bloch, J. Med. Chem., 1972, 15, 735.
• [57] D.A. Carson, D.B. Wasson, J. Kaye, B. Ullman, D.W.J. Martin, R.K. Robins, J.A. Montgomery, Proc. Natl. Acad. Sci. U. S. A., 1980, 77, 6865.
• [58] J.G. Cory, D.A. Rey, G.L. Carter, P.E. Bacon, J. Biol. Chem., 1985, 260, 12001.
• [59] H.M. Bryson, E.M. Sorkin, Drugs, 1993, 46, 872.
• [60] W.B. Parker, Chem. Rev., 2009, 109, 2880.
• [61] W.B. Parker, A.R. Bapat, J.X. Shen, A.J. Townsend, Y.C. Cheng, Mol. Pharmacol., 1988, 34, 485.
• [62] B. Stefanska, K. Rudnicka, A. Bednarek, K. Fabianowska-Majewska, Eur. J. Pharmacol., 2010, 638, 47.
• [63] C. Pierra, S. Benzaria, A. Amador, A. Moussa, S. Mathieu, R. Storer, G. Gosselin, Nucleos. Nucleot. Nucl., 2005, 24, 767.
• [64] J.C. Lee, C.K. Tseng, Y.H. Wu, N. Kaushik-Basu, C.K. Lin, W.C. Chen, H.N. Wu, Antiviral Res., 2015, 116, 1.
• [65] J.L. Clark, L. Hollecker, J.C. Mason, L.J. Stuyver, P.M. Tharnish, S. Lostia, T.R. McBrayer, R.F. Schinazi, K.A. Watanabe, M.J. Otto, P.A. Furman, W.J. Stec, S.E. Patterson, K.W. Pankiewicz, J. Med. Chem., 2005, 48, 5504.
• [66] L. Coelmont, J. Paeshuyse, M.P. Windisch, E. De Clercq, R. Bartenschlager, J. Neyts, Antimicrob. Agents Chemother., 2006, 50, 3444.
• [67] A.B. Eldrup, C.R. Allerson, C.F. Bennett, C.F. Bera, B. Bhat, N. Bhat, M.R. Bosserman, J. Brooks, C. Burlein, S.S. Carroll, P.D. Cook, K.L. Getty, M. MacCoss, D.R. McMasters, D.B. Olsen, T.P. Prakash, M. Prhave, Q. Song, J.E. Tomassini, J. Xia, J. Med. Chem., 2004, 47, 2283.
• [68] A.B. Eldrup, M. Prhavc, J. Brooks, B. Bhat, T.P. Prakesh, J. Med. Chem., 2004, 47, 5284.
• [69] P. Januszczyk, J. Fogt, J. Boryski, I. Kunisuke, T. Onishi, J. Neyts, E. De Clercq, Nucleos. Nucleot. Nucl., 2009, 28, 713.
• [70] M.J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam, S. Rachakonda, P.G. Reddy, B.S. Ross, P. Wang, H.-R. Zhang, S. Bansal, C. Espiritiu, M. Keilman, A.M. Lam, H.M. Steuer, C. Niu, M.J. Otto, P.A. Furman, J. Med. Chem., 2010, 53, 7202.
• [71] C. McGuigan, S.A. Harris, S.M. Daluge, K.S. Gudmundsson, E.W. McLean, T.C. Burnette, H. Marr, R. hazen, L.D. Condreay, L. Johnson, E. De Clercq, J. Balzarini, J. Med. Chem., 2005, 48, 3504.
• [72] R. Flisiak, J. Pogorzelska, M. Flisiak-Jackiewicz, Liver Int., 2017, 37, 26.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018)